Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 2/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.41 |
| ▸ | SUCNR1 | Q9BXA5 | 7/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17764465 | 0.93 | CFD (0.56) | CFDIRAK4SUCNR1HDAC1CTSA | |
| SCHEMBL16409647 | 0.83 | HDAC1 (0.38) | CFDSUCNR1HDAC1GRM2KDM4E | |
| SCHEMBL16410301 | 0.81 | GRM2 (0.45) | SUCNR1HDAC1GRM2CTSANAMPT | |
| SCHEMBL16396451 | 0.81 | HDAC1 (0.44) | CFDSUCNR1HDAC1KDM4ENAMPT | |
| SCHEMBL16410204 | 0.81 | CFD (0.47) | CFDSUCNR1HDAC1NAMPT | |
| SCHEMBL16410308 | 0.80 | LMNA (0.41) | CFDSUCNR1HDAC1GRM2KDM4E | |
| SCHEMBL16410431 | 0.80 | HDAC1 (0.37) | CFDSUCNR1HDAC1GRM2 | |
| SCHEMBL16410357 | 0.80 | HDAC1 (0.41) | CFDSUCNR1HDAC1GRM2KDM4E | |
| SCHEMBL16410346 | 0.79 | HDAC1 (0.36) | CFDSUCNR1HDAC1GRM2KDM4E | |
| SCHEMBL16410368 | 0.79 | HDAC1 (0.44) | CFDSUCNR1HDAC1NAMPTNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | CFD 1/4885IRAK4 1837/4885SUCNR1 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.